Juno Therapeutics — Investor Presentation (March 2016)
27 slides from Juno Therapeutics's investor presentation, Mar 8, 2016
Slide 1: Exhibit 99.1
Exhibit 99.1
Slide 2: Forward-looking statements
Forward-looking statements This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties, and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those exp
Slide 3: Building the leading T cell company
Building the leading T cell company Significant advances in CD19-directed product candidates with a go-to-market strategy defined in ALL and NHL Progress with potential best-in-class product candidates and platform Broad program in solid organ tumors in significant areas of unmet need Building platf
Slide 4: Compelling evidence of rapid tumor shrinkage across multiple clinical trials
Compelling evidence of rapid tumor shrinkage across multiple clinical trials Experience across three leukemia trials demonstrates 82%-100% complete remission rates Most recent strategy in NHL demonstrates 82% overall response rate and 64% complete response rate(1) Day 37 After CD19 CAR T Cells ALL P
Slide 5: Significant unmet need in B cell malignancies
Significant unmet need in B cell malignancies (1)American Cancer Society 2015; Leukemia & Lymphoma Society 2015. Market size numbers from Decision Resources Group. Incidence Annual Deaths ALL NHL CLL/SLL 6,250 42,500 21,080 1,450 19,790 4,650 2015 U.S. Estimates(¹) Market Size ($) $250 Million $3.3
Slide 6: Acute lymphoblastic leukemia (ALL) is an important first market
Source: Adapted from Decision Resource Group and NCCN. Relapsed/Refractory Chemo, Blincyto, include TKI (Ph+), or clinical trials Relapsed/Refractory Chemo, Blincyto, clinical trials, or palliative care 1st line: Induction/ Consolidation/ Maintenance Relapsed / Refractory Acute lymphoblastic leukemi
Slide 7: Encouraging percentage of deep remissions with defined cell product
Encouraging percentage of deep remissions with defined cell product Juno CD19 experience in ALL Goal Product Candidate Potential First-in-class JCAR015 Potential Best-in-class JCAR017 Translational JCAR014 Trial r/r Adult ALL N = 46 Evaluable = 45 r/r Pediatric ALL N = 37 Evaluable = 32 r/r Adult AL
Slide 8: Clinical results in ALL show encouraging survival plateaus
Clinical results in ALL show encouraging survival plateaus Park, ASH 2015 Median overall survival 9.0 months Median follow-up: 5.9 months (1-45+ months) Historical SOC median survival ~3 months (O’Brien, et al, 2008) 0 50 100 0 10 20 30 40 50 Time Since CAR T Cell Infusion (Months) % Overall Surviva
Slide 9: JCAR018: Increasing selection pressure in B cell malignancies
JCAR018: Increasing selection pressure in B cell malignancies The two mechanisms for relapse with CD19 CAR T cells are loss of CAR T cells and loss of CD19 CD22-directed CAR addresses CD19 epitope loss Data at ASH were encouraging with CMRs and the Phase I dose-escalation study is ongoing First clin
Slide 10: DLBCL is a large market opportunity in all lines of therapy
1Roche Financial Report 2015. Adapted from John Leonard, Weill-Cornell Medical College; *Estimated number of patients (SEER 2015). Relapsed/Refractory Transplant ineligible: chemotherapy Diffuse large B cell lymphoma (DLBCL) is a large market opportunity in all lines of therapy Juno’s goal CHOP-R DL
Slide 11: JCAR014: Encouraging data in NHL
Conditioning Regimen Flu/Cy Dose Level 2*105/kg N=3 2*106/kg N=11 2*107/kg N=4-6 Efficacy CR(1) 1/3 (33%) 7/11 (64%) 1/4 (25%) CR/PR 1/3 (33%) 9/11 (82%) 3/4 (75%) Toxicity Severe Cytokine Release Syndrome 0/3 (0%) 1/11 (9%) 3/6 (50%) Severe Neurotoxicity 1/3 (33%) 2/11 (18%) 4/6 (67%) JCAR014: Enco
Slide 12: Juno is building a deep pipeline in NHL
Goal is best-in-class Juno is building a deep pipeline in NHL JCAR017 Enroll multi-center backbone trial, n = ~70 JCAR014 Phase I (ongoing) Develop translational insights (e.g., lymphodepletion) Test checkpoint inhibitor combination Combination trial with anti-PDL1 CD19 / 4-1BBL Test armored CAR 1 2
Slide 13: Early signal in CLL shows potential for CAR T therapy
1AbbVie and Johnson & Johnson Financial Reports 2015. Adapted from reports. Patient numbers include CLL and SLL. Watchful waiting 1st-line treatment 2nd-line treatment Early signal in CLL shows potential for CAR T therapy Juno’s goal Newly diagnosed 2015 Sales Estimate1: Imbruvica® = $1.4B 3rd-line
Slide 14: JCAR014: CLL emerging as a significant opportunity
CRs in patients previously treated with ibrutinib JCAR014: CLL emerging as a significant opportunity Response Assessment Age 36 – 70 years Prior treatment (all treated patients): Median 7 regimens 2 failed prior allogeneic transplant All patients previously treated with ibrutinib Patients For JCAR01
Slide 15: Significant unmet need in multiple myeloma
Significant unmet need in multiple myeloma Incidence Annual Deaths Multiple Myeloma 21,320 11,240 U.S. Estimates(¹) $8.9 Billion (1)Incidence and annual deaths from Seer 2015. Market size based on global sales forecast from EvaluatePharma in 2020. (2)Celgene, Takeda, Amgen Financial Reports 2015. (3
Slide 16: Multiple myeloma is an emerging pipeline opportunity
Multiple myeloma is an emerging pipeline opportunity BCMA Target-X Function Binds BAFF and APRIL; Required for plasma cell survival, not generation; interacts with IRF4 XXXXX Expression Post GC B cells to Plasma cells; not memory B cells Mature B cells to Plasma cells Secreted Yes – increased levels
Slide 17: Significant unmet need in solid tumors
Significant unmet need in solid tumors Incidence Annual Deaths NSCLC (Stage 3b/4) 107,171 132,700 21,920 76,091(2) 49,700 14,180 2015 U.S. Estimates(¹) 88,320 24,000 (1)Incidence and annual deaths obtained through seer.cancer.gov. (2)Incidence represents distant/advance cases (57% of total incidence
Slide 18: Four trials with an opportunity for key learnings in 2016
Four trials with an opportunity for key learnings in 2016 Applying CAR and TCR technology to solid organ tumors Demonstrate that T cells kill cancer – recent checkpoint inhibitor and tumor infiltrating lymphocytes data Demonstrate that T cells home to the tumor Understand and overcome how the tumor
Slide 19: Apply translational insights to overcome the tumor microenvironment
Apply translational insights to overcome the tumor microenvironment Checkpoint Inhibitors Modulating T Cell Function pg/ml IL2 Medi 14736 (anti-PDL1) restores CAR T Function “Armored” CARs E:T Ratio
Slide 20: Active programs in clinical development
Active programs in clinical development The first set of solid tumor targets WT-1 (TCR) AML / NSCLC 15 patients with relapsed / high-risk AML treated with TCR product candidate after HSCT Generally well tolerated; demonstrated safety, persistence and encouraging clinical activity Ongoing studies in
Slide 21: Building a category leader
Building a category leader Manufacturing capabilities JuMP facility online Defined cell product Global reach Celgene collaboration Research capabilities Internal and BD opportunities Strong balance sheet $1.22 billion at year end 2015
Slide 22: Manufacturing infrastructure to support patient supply
Manufacturing infrastructure to support patient supply Facility online to supply clinical material for ongoing Phase II ROCKET trial Capacity for thousands of patients with a scalable and modular design Flexible capacity and able to process multiple products Functionally closed process with extensiv
Slide 23: Controlling the T cell to improve clinical outcomes
Controlling the T cell to improve clinical outcomes Juno investing to control the cells that go into and out of our process Biology insights increasingly confirm that the type of T cell matters
Slide 24: Examples of Juno's capabilities
Cell selection & manipulate extracellular signaling - Stage Targets - Opus Bio / NCI Tumor microenvironment - AstraZeneca / MedImmune Generate binders - AbVitro - X-Body Examples of Juno’s capabilities Capability development to support goal of best-in-class Change DNA - Editas - CAR T technology Mod
Slide 25: Solidifying leadership in the development of transformative immunotherapies
Solidifying leadership in the development of transformative immunotherapies BUSINESS DEVELOPMENT COOPERATION EXPANDED CAPABILITIES ACCELERATED PIPELINE PIPELINE ENHANCEMENT Cell therapies, small molecules, and proteins Immuno-oncology combinations Deep translational capabilities Global commercializa
Slide 26: Juno's goals for value creation
Juno’s goals for value creation Execute Leukemia Potential First in Class: JCAR015 Adult ALL Potential Best in Class: JCAR017 Ped ALL CD19- Disease: JCAR018 Human CD19: JCAR021 Transform Lymphoma JCAR017 JCAR014 PD-L1 Combination Beyond B Cell Malignancies to Solid Tumors Target Selection JCAR024 (R
Slide 27: Program Description
Program Description CD19: JCAR015 (Adult ALL and Adult NHL) Adult ALL Phase I Adult NHL (Post Autologous Tx) Phase I Adult ALL Phase II Pivotal Study CD19: JCAR017 (Pediatric ALL and Adult NHL) Pediatric ALL Phase I / II Adult NHL Phase I CD19: JCAR014 (Adult B Cell Malignancies) Adult B Cell Malign
Juno Therapeutics — Investor Presentation (March 2016) on 6ix